The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Ocrevus

300 milligram(s) Concentrate for solution for infusion

Roche Registration GmbHEU/1/17/1231/001-002

Main Information

Trade NameOcrevus
Active SubstancesOcrelizumab
Strength300 milligram(s)
Dosage FormConcentrate for solution for infusion
Licence HolderRoche Registration GmbH
Licence NumberEU/1/17/1231/001-002

Group Information

ATC CodeL04AA Selective immunosuppressants
L04AA36 ocrelizumab

Status

Authorised/WithdrawnAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back